Elevated plasma tissue factor and D-dimer concentrations observed in patients with COVID-19 suggest that these mediators may be useful markers of ongoing endothelial dysfunction and hypercoagulability and warrant further investigation of tissue factor as a possible therapeutic target (ClinicalTrials.gov identifier: NCT04655586). Here, F3 is linked to thrombophilia.